Andrew D. Mesecar

Andrew D. Mesecar

Purdue University

H-index: 69

North America-United States

About Andrew D. Mesecar

Andrew D. Mesecar, With an exceptional h-index of 69 and a recent h-index of 43 (since 2020), a distinguished researcher at Purdue University, specializes in the field of Structure-based drug design, cancer, coronavirus, COVID-19, Alzheimers Disease.

His recent articles reflect a diverse array of research interests and contributions to the field:

Compounds for the treatment of sars

A novel micellular fluorogenic substrate for quantitating the activity of 1-phosphatidylinositol 4, 5-bisphosphate phosphodiesterase gamma (PLCγ) enzymes

Exploration of P1 and P4 modifications of nirmatrelvir: Design, synthesis, biological evaluation, and X-ray structural studies of SARS-CoV-2 Mpro inhibitors

pH-dependent reaction triggering in PmHMGR crystals for time-resolved crystallography

SARS-CoV-2 papain-like protease (PLpro) inhibitory and antiviral activity of small molecule derivatives for drug leads

6-amino-2, 4-dihydropyrano [2, 3-c] pyrazoles and methods of use

SHIP1 therapeutic target enablement: Identification and evaluation of inhibitors for the treatment of late‐onset Alzheimer's disease

Targeting Enterococcus faecalis HMG-CoA reductase with a non-statin inhibitor

Andrew D. Mesecar Information

University

Position

Walther Professor of Structural Biology Department of Biochemistry

Citations(all)

17269

Citations(since 2020)

8774

Cited By

12227

hIndex(all)

69

hIndex(since 2020)

43

i10Index(all)

145

i10Index(since 2020)

118

Email

University Profile Page

Purdue University

Google Scholar

View Google Scholar Profile

Andrew D. Mesecar Skills & Research Interests

Structure-based drug design

cancer

coronavirus

COVID-19

Alzheimers Disease

Top articles of Andrew D. Mesecar

Title

Journal

Author(s)

Publication Date

Compounds for the treatment of sars

2024/2/8

A novel micellular fluorogenic substrate for quantitating the activity of 1-phosphatidylinositol 4, 5-bisphosphate phosphodiesterase gamma (PLCγ) enzymes

Plos one

Ramya Visvanathan

Tadanobu Utsuki

Daniel E Beck

W Brent Clayton

Emma Lendy

...

2024/3/29

Exploration of P1 and P4 modifications of nirmatrelvir: Design, synthesis, biological evaluation, and X-ray structural studies of SARS-CoV-2 Mpro inhibitors

European Journal of Medicinal Chemistry

Arun K Ghosh

Monika Yadav

Satyanarayana Iddum

Somayeh Ghazi

Emma K Lendy

...

2024/3/5

pH-dependent reaction triggering in PmHMGR crystals for time-resolved crystallography

Biophysical Journal

Vatsal Purohit

Calvin N Steussy

Anthony R Rosales

Chandra J Critchelow

Tim Schmidt

...

2024/2/6

SARS-CoV-2 papain-like protease (PLpro) inhibitory and antiviral activity of small molecule derivatives for drug leads

Bioorganic & Medicinal Chemistry Letters

Arun K Ghosh

Dana Shahabi

Mackenzie EC Imhoff

Satish Kovela

Ashish Sharma

...

2023/11/15

6-amino-2, 4-dihydropyrano [2, 3-c] pyrazoles and methods of use

2023/4/4

SHIP1 therapeutic target enablement: Identification and evaluation of inhibitors for the treatment of late‐onset Alzheimer's disease

Alzheimer's & Dementia: Translational Research & Clinical Interventions

Cynthia D Jesudason

Emily R Mason

Shaoyou Chu

Adrian L Oblak

June Javens‐Wolfe

...

2023/10

Targeting Enterococcus faecalis HMG-CoA reductase with a non-statin inhibitor

Communications Biology

Sucharita Bose

C Nicklaus Steussy

Daneli López-Pérez

Tim Schmidt

Samadhi C Kulathunga

...

2023/4/3

Development of a sensitive microplate assay for characterizing RNA methyltransferase activity: Implications for epitranscriptomics and drug development

Journal of Biological Chemistry

Isaiah K Mensah

Allison B Norvil

Ming He

Emma Lendy

Nicole Hjortland

...

2023/10/1

Genetic variants of phospholipase C-γ2 alter the phenotype and function of microglia and confer differential risk for Alzheimer’s disease

Immunity

Andy P Tsai

Chuanpeng Dong

Peter Bor-Chian Lin

Adrian L Oblak

Gonzalo Viana Di Prisco

...

2023/9/12

A target enablement package for modulating the activity of PLCγ2 as a therapeutic strategy for the treatment of Alzheimer’s disease

Alzheimer's & Dementia

Brent Clayton

Stephanie J Bissel

Timothy I Richardson

Steven M Massey

Daniel E Beck

...

2023/12

A novel fluorogenic reporter substrate for 1-phosphatidylinositol 4, 5-bisphosphate phosphodiesterase gamma-2 (PLCγ2): Application to high-throughput screening for activators …

SLAS Discovery

Ramya Visvanathan

Tadanobu Utsuki

Daniel E Beck

Emma Lendy

Kuai-lin Sun

...

2023/6/1

Recent drug development and medicinal chemistry approaches for the treatment of SARS‐CoV‐2 infection and COVID‐19

Arun K Ghosh

Jennifer L Mishevich

Andrew Mesecar

Hiroaki Mitsuya

2022/11/18

Desorption electrospray ionization mass spectrometry assay for label‐free characterization of SULT2B1b enzyme kinetics

Journal of the American Society for Mass Spectrometry

Jephte Yao Akakpo

Matthew Wolfgang Jaeschke

Yasaman Etemadi

Antonio Artigues

Scott Toerber

...

2022/10/12

Exploring the structural determinants for inhibitor selectivity towards the BACE protein family using structure-based molecular design

Biophysical Journal

Emma K Lendy

Yu-Chen Yen

Emilio L Cardenas

Margherita Brindisi

Arun K Ghosh

...

2022/2/11

Genetic Variants of Phospholipase C-γ2 Confer Altered Microglial Phenotypes and Differential Risk for Alzheimer’s Disease

bioRxiv

Andy P Tsai

Chuanpeng Dong

Peter Bor-Chian Lin

Adrian L Oblak

Gonzalo Viana Di Prisco

...

2022/12/9

Bace1 inhibitors for the treatment of alzheimer's disease

2022/12/8

Characterization of human sulfotransferase 1A1 (SULT1A1) as a new target for structure-based design of drugs to treat cancer

Biophysical Journal

Samadhi C Kulathunga

Qing Zhou

Nicolás M Morato

R Graham Cooks

Andrew D Mesecar

2022/2/11

Catalytic function and substrate specificity of alpha and beta coronavirus papain-like proteases: targeting human NL63, SARS-CoV and SARS-CoV-2 (Covid-19) with designed inhibitors

Biophysical Journal

Mackenzie E Chapman

Courtney M Daczkowski

Arun K Ghosh

Andrew D Mesecar

2022/2/2

A target enablement package for the inhibition of SHIP1 as a therapeutic strategy for the treatment of Alzheimer’s disease

Alzheimer's & Dementia

Timothy I Richardson

Cynthia D Jesudason

Karen L Lobb

Gregory L Durst

Brent Clayton

...

2022/12

See List of Professors in Andrew D. Mesecar University(Purdue University)

Co-Authors

H-index: 91
Richard B van Breemen

Richard B van Breemen

Oregon State University

H-index: 76
Susan C. Baker

Susan C. Baker

Loyola University Chicago

H-index: 73
Harry H. S. Fong

Harry H. S. Fong

University of Illinois at Chicago

H-index: 73
Mark Cushman

Mark Cushman

Purdue University

H-index: 63
Judy L Bolton

Judy L Bolton

University of Illinois at Chicago

H-index: 59
Bernard D Santarsiero

Bernard D Santarsiero

University of Illinois at Chicago

academic-engine